14:07 ET -- Novartis AG is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Novartis said Thursday it would pay $245 million to end antitrust cases accusing the Swiss pharmaceutical company of anticompetitive conduct in the U.S. The settlement relates to a 2011 license agreement between Novartis and Par Pharmaceutical Inc. in which Par delayed the introduction of a generic drug that would compete with Novartis's prescription drug Exforge, a blood pressure regulator. Shares of Novartis recently traded 1% higher at $91.76. Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)

(END) Dow Jones Newswires

December 29, 2022 14:23 ET (19:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Novartis.